OBJECTIVE: The programmed cell death-1 receptor/programmed cell death-1 ligand (PD-1/PD-L1) pathway plays a crucial role in tumor evasion from host immunity. This study was designed to evaluate the association between circulating PD-L1 expression and prognosis in patients with advanced gastric cancer. METHODS: Totally 80 advanced gastric cancer patients and 40 health controls from Beijing Cancer Hospital were enrolled in the present study. Circulating PD-L1 expression was tested by enzyme-linked immunosorbent assay (ELISA). The associations between the expression level of PD-L1 and clinicopathological features and prognosis were analyzed statistically. RESULTS: Expression of PD-L1 in advanced gastric cancer patients was significantly up-regulated compared with health people (P=0.006). The expression of PD-L1 was significantly correlated with differentiation and lymph node metastasis (P=0.026 and P=0.041, respectively). Although we didn't find significant difference in all advanced gastric cancer patients with different PD-L1 expression, the adenocarcinoma patients with higher up-regulated PD-L1 expression had much better prognosis than low expression patients (65.6% vs. 44.7%, P=0.028). CONCLUSIONS: PD-L1 was elevated in advance gastric cancer patients and may play an important role in tumor immune evasion and patients prognosis.
OBJECTIVE: The programmed cell death-1 receptor/programmed cell death-1 ligand (PD-1/PD-L1) pathway plays a crucial role in tumor evasion from host immunity. This study was designed to evaluate the association between circulating PD-L1 expression and prognosis in patients with advanced gastric cancer. METHODS: Totally 80 advanced gastric cancerpatients and 40 health controls from Beijing Cancer Hospital were enrolled in the present study. Circulating PD-L1 expression was tested by enzyme-linked immunosorbent assay (ELISA). The associations between the expression level of PD-L1 and clinicopathological features and prognosis were analyzed statistically. RESULTS: Expression of PD-L1 in advanced gastric cancerpatients was significantly up-regulated compared with health people (P=0.006). The expression of PD-L1 was significantly correlated with differentiation and lymph node metastasis (P=0.026 and P=0.041, respectively). Although we didn't find significant difference in all advanced gastric cancerpatients with different PD-L1 expression, the adenocarcinomapatients with higher up-regulated PD-L1 expression had much better prognosis than low expression patients (65.6% vs. 44.7%, P=0.028). CONCLUSIONS:PD-L1 was elevated in advance gastric cancerpatients and may play an important role in tumor immune evasion and patients prognosis.
Authors: Li Wang; Karina Pino-Lagos; Victor C de Vries; Indira Guleria; Mohamed H Sayegh; Randolph J Noelle Journal: Proc Natl Acad Sci U S A Date: 2008-07-02 Impact factor: 11.205
Authors: Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick Journal: J Gastrointest Surg Date: 2005 May-Jun Impact factor: 3.452
Authors: Iris Simon; Shaoqiu Zhuo; Laura Corral; Eleftherios P Diamandis; Mark J Sarno; Robert L Wolfert; Nam W Kim Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701
Authors: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg Journal: Blood Date: 2009-05-07 Impact factor: 22.113
Authors: Stephan Kruger; Marie-Louise Legenstein; Verena Rösgen; Michael Haas; Dominik Paul Modest; Christoph Benedikt Westphalen; Steffen Ormanns; Thomas Kirchner; Volker Heinemann; Stefan Holdenrieder; Stefan Boeck Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu Journal: Oncoimmunology Date: 2016-11-22 Impact factor: 8.110
Authors: Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay Journal: Cancer Immunol Immunother Date: 2018-12-18 Impact factor: 6.968